ClinicalTrials.gg
CompletedNCT06532370Updated Oct 8, 2026

Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii

An interventional study of Contingency Managment in Contingency Managment and Methamphetamine Use Disorder, sponsored by Queen's Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Queen's Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 8, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use.

The main objectives are to:

  • Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury
  • To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.

Participants will:

  • Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit
  • Complete Treatment Effectiveness Assessments at 6 and 12-weeks
  • Engage in a qualitative interview at the end of the CM program
02

Conditions studied

  • Contingency Managment
  • Methamphetamine Use Disorder
03

In context

Lead sponsor

Queen's Medical Center is the lead sponsor of 20 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted trauma patients
  • Age greater than 18 years old
  • Urine drug screen positive for methamphetamines during the current hospitalization
  • Report at least weekly methamphetamine use
  • First methamphetamine use greater than 6 months prior to injury
  • Report at least 4 Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)
  • Glasgow Coma Scale ≥13 upon arrival to the emergency department
  • Ability to understand and participate in study procedures
  • Ability to communicate in English

Exclusion criteria

Exclusion Criteria:

  • Active psychosis (reporting auditory or visual hallucinations)
  • Under ongoing cardiorespiratory monitoring
  • Evidence of moderate or severe traumatic brain injury
  • Patients who are known to be pregnant
  • Prisoner
  • Individuals incarcerated at the time of their hospitalization
  • Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Contingency Managment

    Participants are allowed to complete CM three times per week for the maximum of 12-weeks. At the six- and 12-week time points, participants will complete the Treatment Effectiveness Assessment (TEA) with study personnel.

    Behavioral: Contingency Managment

Interventions

  • BehavioralContingency Managment

    If the sample be methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately, half of the slips offer written praise (e.g. "great job!"). The other half of slips are then divided between low value (e.g. food gift cards, bus passes), medium value (e.g. prepaid cell phone, clothing gift cards), and a few large value rewards (e.g. iPad, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date.

06

What researchers measure

Primary outcomes

  1. TEA Outcomes at 6 and 12-weeks

    Treatment Effectiveness Assessment (TEA): This assessment asks individuals to respond to changes in four domains following a drug treatment program: substance use, health, lifestyle, and community. The score for each domain can range from 1 (no change or not much) to 10 (much better), for a total score of 4-40. This score allows for the prioritization of each participants values, and therefore does not require strict abstinence to demonstrate benefit from drug treatment.

    Time frame: From enrollment to 6 and 12-weeks

Secondary outcomes

  1. Qualitative Outcomes

    Interviews will be conducted as semi-structured interviews using a priori interview guides. Interviews will be transcribed and analyzed using a Template Analysis approach. Two coders will conduct coding of the interview data to ultimately identify themes that will be used as the basis for interpretation. The final analysis of the qualitative data will include contrasts and comparisons made across interviews to examine overlaps and divergences across any relevant sub-samples (e.g., sex, age). Results will present thematic patterns, how frequently each code occurs, and any contradictory evidence.

    Time frame: At the end of treatment at 12-weeks

Other outcomes

  1. Urine Analysis Results

    Study personnel will ask participant to complete a urine analysis screen. Following completion of the urinalysis, study personnel will use a test strip to determine if the sample is methamphetamine negative or positive. Results will be documented and analyzed for a reduction in methamphetamine.

    Time frame: From enrollment to the end of treatment at 12-weeks

07

Study locations

1 site
  • The Queen's Medical Center
    Honolulu, Hawaii 90813, United States
08

References and documents

Publications

  • Gold MS, Kobeissy FH, Wang KK, Merlo LJ, Bruijnzeel AW, Krasnova IN, Cadet JL. Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol Psychiatry. 2009 Jul 15;66(2):118-27. doi: 10.1016/j.biopsych.2009.02.021. Epub 2009 Apr 5. PubMed 19345341 ↗
  • El Moheb M, Herrera-Escobar JP, Breen K, Orlas C, Haynes AN, Levy-Carrick NC, Nehra D, Sanchez SE, Salim A, Velmahos G, Kaafarani HMA. Long-term outcomes of psychoactive drug use in trauma patients: A multicenter patient-reported outcomes study. J Trauma Acute Care Surg. 2021 Feb 1;90(2):319-324. doi: 10.1097/TA.0000000000003032. PubMed 33264267 ↗
  • Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, Wood E, Fairbairn N. Treatment of stimulant use disorder: A systematic review of reviews. PLoS One. 2020 Jun 18;15(6):e0234809. doi: 10.1371/journal.pone.0234809. eCollection 2020. PubMed 32555667 ↗
  • Ling W, Nadipelli VR, Solem CT, Farabee D, Ronquest NA, Perrochet B, Learned SM, Deshpande CG, Heidbreder C. Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. Subst Abuse Rehabil. 2019 Jun 5;10:13-21. doi: 10.2147/SAR.S198361. eCollection 2019. PubMed 31239805 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2024 to primary completion in Sep 2026, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 1, 2024
StartActual
Oct 10, 2024
Primary completionActual
Sep 30, 2026was Dec 2026
CompletionActual
Sep 30, 2026was Dec 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 8, 2026
Primary completion
Dec 30, 2026→Sep 30, 2026 (actual)
Oct 8, 2026
Study completion
Dec 30, 2026→Sep 30, 2026 (actual)
Oct 8, 2026
Enrollment
40 (estimated)→39 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Completed
    Primary completion Dec 30, 2026→Sep 30, 2026 (now actual)
    Study completion Dec 30, 2026→Sep 30, 2026 (now actual)
    Enrollment 40 (estimated)→39 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06532370
Lead sponsor
Queen's Medical Center
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Oct 10, 2024
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Oct 8, 2026

Study contacts

Todd Seto, MD
study chair · The Queens Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion